Amyloid fibril formation by a partially structured intermediate state of α-chymotrypsin I Pallarès, J Vendrell, FX Avilés, S Ventura Journal of molecular biology 342 (1), 321-331, 2004 | 251 | 2004 |
Prediction of" hot spots" of aggregation in disease-linked polypeptides NS De Groot, I Pallarés, FX Avilés, J Vendrell, S Ventura BMC Structural Biology 5, 1-15, 2005 | 238 | 2005 |
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity R Sant'Anna, P Gallego, LZ Robinson, A Pereira-Henriques, N Ferreira, ... Nature communications 7 (1), 10787, 2016 | 163 | 2016 |
Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin I Pallarès, R Bonet, R García-Castellanos, S Ventura, FX Avilés, ... Proceedings of the National Academy of Sciences 102 (11), 3978-3983, 2005 | 123 | 2005 |
Dissecting the contribution of Staphylococcus aureus α-phenol-soluble modulins to biofilm amyloid structure P Marinelli, I Pallares, S Navarro, S Ventura Scientific reports 6 (1), 34552, 2016 | 71 | 2016 |
α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity J Santos, P Gracia, S Navarro, S Peña-Díaz, J Pujols, N Cremades, ... Nature communications 12 (1), 3752, 2021 | 56 | 2021 |
Computational prediction of protein aggregation: Advances in proteomics, conformation-specific algorithms and biotechnological applications J Santos, J Pujols, I Pallarès, V Iglesias, S Ventura Computational and structural biotechnology journal 18, 1403-1413, 2020 | 56 | 2020 |
pH-dependent aggregation in intrinsically disordered proteins is determined by charge and lipophilicity J Santos, V Iglesias, J Santos-Suárez, M Mangiagalli, S Brocca, I Pallarès, ... Cells 9 (1), 145, 2020 | 55 | 2020 |
Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis L Sanglas, Z Valnickova, JL Arolas, I Pallarés, T Guevara, M Solà, ... Molecular cell 31 (4), 598-606, 2008 | 51 | 2008 |
Chemical chaperones as novel drugs for Parkinson’s disease J Pujols, S Peña-Díaz, I Pallarès, S Ventura Trends in molecular medicine 26 (4), 408-421, 2020 | 50 | 2020 |
Progress in metallocarboxypeptidases and their small molecular weight inhibitors D Fernández, I Pallarès, J Vendrell, FX Avilés Biochimie 92 (11), 1484-1500, 2010 | 50 | 2010 |
Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis F Pinheiro, N Varejão, S Esperante, J Santos, A Velázquez‐Campoy, ... The FEBS Journal 288 (1), 310-324, 2021 | 44 | 2021 |
The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa∗♦ K Anand, I Pallares, Z Valnickova, T Christensen, J Vendrell, KU Wendt, ... Journal of biological chemistry 283 (43), 29416-29423, 2008 | 44 | 2008 |
Discovering putative prion-like proteins in Plasmodium falciparum: a computational and experimental analysis I Pallarès, NS De Groot, V Iglesias, R Sant’Anna, A Biosca, ... Frontiers in microbiology 9, 381158, 2018 | 42 | 2018 |
The Rho termination factor of Clostridium botulinum contains a prion-like domain with a highly amyloidogenic core I Pallarès, V Iglesias, S Ventura Frontiers in microbiology 6, 177351, 2016 | 37 | 2016 |
A functional and structural study of the major metalloprotease secreted by the pathogenic fungus Aspergillus fumigatus D Fernandez, S Russi, J Vendrell, M Monod, I Pallares Acta Crystallographica Section D: Biological Crystallography 69 (10), 1946-1957, 2013 | 36 | 2013 |
Understanding and predicting protein misfolding and aggregation: Insights from proteomics I Pallarès, S Ventura Proteomics 16 (19), 2570-2581, 2016 | 32 | 2016 |
Detailed molecular comparison between the inhibition mode of A/B-type carboxypeptidases in the zymogen state and by the endogenous inhibitor latexin R Garcia-Castellanos, R Bonet-Figueredo, I Pallares, S Ventura, ... Cellular and Molecular Life Sciences CMLS 62, 1996-2014, 2005 | 28 | 2005 |
Advances in the prediction of protein aggregation propensity I Pallarès, S Ventura Current Medicinal Chemistry 26 (21), 3911-3920, 2019 | 27 | 2019 |
Metallocarboxypeptidases and their inhibitors: Recent developments in biomedically relevant protein and organic ligands D Fernández, I Pallarès, G Covaleda, F X Aviles, J Vendrell Current Medicinal Chemistry 20 (12), 1595-1608, 2013 | 23 | 2013 |